Natera and Guardant are about to shake things up with indication-specific blood tests, but Exact is keeping faith with Cologuard – for now.
Big-cap device makers on European exchanges did nicely in 2021, whereas their US-listed brethren had a harder time.
Device deal making is back in a big way, despite the munificence of venture funds.
Shareholders are rewarding the kinds of companies they punished a year ago.
And an expanded market awaits its colorectal cancer blood test, though Exact will benefit first.
The quest for the Grail is beset with challenges.